Briefcase

Switching ART Due to Treatment Resistance

Launch Date
07/26/2023
Credit Amount
0.5
Credit Expires
07/26/2024
This activity is part of a series

Faculty

Debbie P. Hagins, MD, FAPCR, AAHIVS
HIV Program Director
Medical Director and Principal Investigator
Coastal Health District’s CARE Clinics
Savannah, GA
Debbie P. Hagins, MD, FAPCR, AAHIVS

Debbie P. Hagins, MD, FAPCR, AAHIVS, is the Medical Director and Principal Investigator for Coastal Health District’s CARE clinics in Savannah, Georgia, and surrounding counties, and has more than 30 years of experience as a family medicine doctor. Dr. Hagins received her HIV Specialist certification from the American Academy of HIV Medicine and is a Fellow of the Academy of Physicians of Clinical Research, a designation reserved for Academy members who have shown significant commitment to, and achievement in, clinical research. Dr. Hagins graduated from Morehouse School of Medicine and completed her residency at Memorial Health University Medical Center in Savannah, Georgia. She has been recognized as Unstoppable Woman of the Year, received the Georgia State Public Health Primary Care Leadership award, and the Hero in Medicine award. She has been featured in The New York Times, the Wall Street Journal, local papers, and has been a guest on several radio and television outlets. Dr. Hagins has been involved in community health events for more than 30 years, presenting on a range of health topics.

Sorana Segal-Maurer, MD
Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases, NewYork-Presbyterian Queens
Professor of Clinical Medicine, Weill Cornell Medical College, Cornell University
New York, NY
Sorana Segal-Maurer, MD

Sorana Segal-Maurer, MD is Director of Infectious Diseases at NewYork-Presbyterian Queens in Flushing, NY and Professor of Clinical Medicine at Weill Cornell Medicine in New York, NY. She has published extensively, as author of peer-reviewed articles on HIV treatment adherence, diagnosis, and treatment of metabolic and morphologic changes in HIV infected patients, and is an author of the section, “Nutritional Metabolism and Support in the Setting of HIV Infection“, in the Adult Nutrition Support Core Curriculum textbook. She is actively involved in HIV research, serving as principal investigator or co-investigator in phase II, III, IV clinical trials as well as investigator-initiated trials. Currently, she is the lead author on the 2022 NEJM publication of the CAPELLA trial where the use of lenacapavir was evaluated in a cohort of heavily treated persons living with HIV. She has been in clinical practice for nearly 30 years.

Dr. Segal-Maurer is board-certified in infectious diseases and is a Diplomate of the American Board of Medical Examiners. She received her medical degree from Icahn School of Medicine in New York, NY and completed an internship, residency, and infectious diseases fellowship at Albert Einstein College of Medicine/Montefiore Medical Center in Bronx, NY.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Although infrequent, treatment resistance to antiretroviral therapy (ART) can occur when HIV pre-exposure prophylaxis (PrEP) HIV medications are started or continued following an undiagnosed acute HIV infection or when HIV treatment and/or adherence to treatment is suboptimal. With various PrEP and ART treatments available, clinicians require education on how to counter drug resistance, when to switch ART treatments, how to find the best treatment options for their patients, how to educate their patients on the importance of medication adherence, and how to monitor progress after switching therapies.

This CMEO BriefCase entitled, Switching Antiretroviral Therapy (ART) Due to Treatment Resistance, will discuss the specific case of an individual who experiences resistance to ART treatment. Expert faculty will discuss recognizing when treatment resistance occurs, why it may occur, and ways to switch treatments and monitor outcomes for patients experiencing treatment resistance.

Learning Objective

Implement ART switching strategies to overcome HIV treatment resistance.

Financial Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in HIV.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-074-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Hagins reports no financial relationships to disclose. She is an uncompensated volunteer participant in speaker trainings, ad boards and on the speaker’s bureau for Gilead Sciences, Inc.; GSK/ViiV Healthcare; and Janssen Pharmaceuticals, inc. since July 2021.

Dr. Segal-Maurer reports the following financial relationships:

Advisory Board: Gilead Sciences, Inc.; Janssen Therapeutics; Theratechnologies Inc.; and ViiV Healthcare

Consultant: Gilead Sciences, Inc.; Janssen Therapeutics; Lumanity Inc.; Theratechnologies Inc.; Veradigm LLC; and ViiV Healthcare

Research Support: Gilead Sciences, Inc. to NYPQ (no support to Dr. Segal-Maurer)

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Joshua Caballero PharmD, BCPP, FCCP (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • Kellie Busby, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-094-072623-47

Switching ART Due to Treatment Resistance
Event Date: 07/26/2023
Register

Activities in the Series

Infectious Disease
09/07/2023

People Living with HIV (PLWH) and Substance Abuse Disorder (SUD): Addressing Barriers to Viral Suppression

0.75
Register Learn More
Infectious Disease
08/04/2023

ART for PLWH Who Are Pregnant or of Childbearing Potential

0.75
Register Learn More
Infectious Disease
07/26/2023

Switching ART Due to Treatment Resistance

0.5
Register Learn More